Revolution Medicines (RVMD) Earnings Transcript [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Chairman and Chief Executive Officer — Dr. Mark A. Goldsmith Chief Financial Officer — Jack Anders President of Research and Development — Dr. Stephen M. Kelsey Chief Development Officer — Dr. Alan Bart Sandler Chief Medical Officer — Dr. Wei Lin Chief Global Commercialization Officer — Anthony Mancini Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Ryan Asay: Thank you, and welcome, everyone, to our fourth quarter and full year 2025 earnings call. Joining me on today's call are Dr. Mark A. Goldsmith, our Chairman and Chief Executive Officer, and Jack Anders, our Chief Financial Officer. Dr. Stephen M. Kelsey, our President of Research and Development, Dr. Alan Bart Sandler, our Chief Development Officer, Dr. Wei Lin, our Chief Medical Officer, and Anthony Mancini, our Chief Global Commercialization Officer, will join us for the Q&A portion of today's call. Before we begin, I would like to remind everyone that certain stateme
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) is now covered by UBS Group AG. They set a "buy" rating and a $145.00 price target on the stock.MarketBeat
- Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here's Why [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 3/6/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- RVMD's page on the SEC website